RBDCOV initiates the first Phase III clinical trial of HIPRA’s Covid-19 vaccine in immunocompromised people


One of the objective of RBDCOV is to test whether the vaccine can reactivate or re-generate a protective immune response against the virus

The RBDCOV project, in which Penta is a partner, started a Phase III clinical trial of the Covid-19 vaccine in immunocompromised people, after the Spanish Agency for Medicines and Health Products (AEMPS) authorised it on 9 May. This clinical trial will determine whether an additional dose of HIPRA’s Covid-19 vaccine can generate an immune response in people living with immune system disorders,

Read More